← Eichor
Study identifier: NCT03684018 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Two Dose Levels of Privigen in Pediatric CIDP

Condition: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)  ·  Sponsor: CSL Behring

PhasePhase 4
Planned participants30
Who can joinAll sexes, 2 Years to 17 Years
Healthy volunteersNo

About this study

A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment

This description comes directly from the study's public registry record.

Talk to the study team

Trial Registration Coordinator  ·  6108784697  ·  clinicaltrials@cslbehring.com

Always discuss trial participation with your own doctor first.

Locations (9)

Phoenix Children's HospitalPhoenix, Arizona, United StatesCompleted
Children's Hospital of Los AngelesLos Angeles, California, United StatesWithdrawn
University of Iowa Hospitals and ClinicsIowa City, Iowa, United StatesWithdrawn
Akron Children's HospitalAkron, Ohio, United StatesWithdrawn
Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania, United StatesRecruiting
Le Bonheur Children's HospitalMemphis, Tennessee, United StatesWithdrawn
Neurology Rare Disease CenterFlower Mound, Texas, United StatesRecruiting
Children's Specialty GroupNorfolk, Virginia, United StatesCompleted
Seattle Children's HospitalSeattle, Washington, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03684018